News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
758,222 Results
Type
Article (54664)
Company Profile (371)
Press Release (703187)
Section
Business (220006)
Career Advice (2917)
Deals (38048)
Drug Delivery (116)
Drug Development (87392)
Employer Resources (184)
FDA (17326)
Job Trends (16294)
News (373912)
Policy (36357)
Tag
Academia (2911)
Alliances (53736)
Alzheimer's disease (1396)
Approvals (17261)
Artificial intelligence (202)
Bankruptcy (384)
Best Places to Work (12299)
Biotechnology (247)
Breast cancer (223)
Cancer (1669)
Cardiovascular disease (141)
Career advice (2445)
CAR-T (120)
Cell therapy (347)
Clinical research (69920)
Collaboration (639)
Compensation (323)
COVID-19 (2799)
C-suite (149)
Data (1534)
Diabetes (211)
Diagnostics (6620)
Earnings (89337)
Employer resources (161)
Events (120099)
Executive appointments (535)
FDA (18152)
Funding (560)
Gene therapy (249)
GLP-1 (752)
Government (4858)
Healthcare (20214)
Infectious disease (2903)
Inflammatory bowel disease (129)
Interviews (559)
IPO (17234)
Job creations (4451)
Job search strategy (2025)
Layoffs (487)
Legal (9018)
Lung cancer (250)
Manufacturing (242)
Medical device (14026)
Medtech (14031)
Mergers & acquisitions (21084)
Metabolic disorders (584)
Neuroscience (1813)
NextGen: Class of 2025 (7218)
Non-profit (4920)
Northern California (1937)
Obesity (335)
Opinion (245)
Patents (145)
People (62193)
Phase I (21703)
Phase II (30626)
Phase III (22964)
Pipeline (643)
Postmarket research (2990)
Preclinical (9257)
Radiopharmaceuticals (259)
Rare diseases (327)
Real estate (6654)
Regulatory (24218)
Research institute (2580)
Resumes & cover letters (461)
Southern California (1683)
Startups (3973)
United States (17718)
Vaccines (674)
Weight loss (256)
Date
Today (133)
Last 7 days (636)
Last 30 days (2452)
Last 365 days (36766)
2025 (2371)
2024 (37215)
2023 (42100)
2022 (53394)
2021 (58092)
2020 (56915)
2019 (50189)
2018 (38038)
2017 (35171)
2016 (35225)
2015 (41226)
2014 (35449)
2013 (30748)
2012 (32662)
2011 (33234)
2010 (31387)
Location
Africa (953)
Arizona (219)
Asia (44359)
Australia (7741)
California (4463)
Canada (1598)
China (387)
Colorado (201)
Connecticut (222)
Europe (97449)
Florida (639)
Georgia (155)
Illinois (466)
Indiana (262)
Maryland (737)
Massachusetts (3498)
Michigan (196)
Minnesota (337)
New Jersey (1262)
New York (1272)
North Carolina (886)
Northern California (1937)
Ohio (164)
Pennsylvania (1029)
South America (1355)
Southern California (1683)
Texas (661)
Utah (129)
Washington State (453)
758,222 Results for "s1 biopharma formerly known as s1 pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
GLP-1
Evidence Mounts for Potential of GLP-1s in Alzheimer’s Disease
The darlings of the weight loss and diabetes spaces, GLP-1 receptor agonists have shown promise against Alzheimer’s in recent studies—with Phase III results expected next year from Novo Nordisk.
December 9, 2024
·
6 min read
·
Heather McKenzie
Drug shortages
FDA Confirms Lilly’s GLP-1s Are Not in Shortage, Gives Compounders Grace Period
After a couple months of uncertainty, the FDA has told compounding pharmacies that they have 60 to 90 days before the agency will enforce rules to stop their production of GLP-1s.
December 19, 2024
·
3 min read
·
Tristan Manalac
Press Releases
Averna Therapeutics, formerly known as Exsilio Therapeutics, Appoints Thomas M. Barnes, Ph.D., as Chief Executive Officer
January 27, 2025
·
3 min read
Press Releases
Sunshine Biopharma Announces Breakthrough Research Results on the Company’s K1.1 mRNA Product as a Novel Therapeutic Agent for Human Hepatocellular Carcinoma
December 2, 2024
·
3 min read
Drug shortages
Legal Challenge Over Lilly’s GLP-1 Shortages Highlights FDA’s Post-Chevron Vulnerability
Currently, Eli Lilly’s GLP-1 drugs Mounjaro and Zepbound (tirzepatide) are not on the FDA’s shortage list but compounded pharmacies are still making them. That’s unprecedented.
November 26, 2024
·
4 min read
·
Ben Hargreaves
Press Releases
CG Pharmaceuticals: Progress of U.S. Phase 1b/2 Metastatic Pancreatic Cancer Clinical Trial at the ASCO Gastrointestinal Symposium
January 23, 2025
·
4 min read
FDA Tracker
2024 Ends With Lilly’s Landmark GLP-1 Sleep Apnea Approval
Other notable greenlights this year include Bristol Myers Squibb’s Cobenfy, the first novel therapeutic for schizophrenia in 35 years, and Madrigal Pharmaceuticals’ Rezdiffra, the first-ever treatment for MASH.
December 24, 2024
·
223 min read
·
BioSpace Editorial Staff
GLP-1
7 Indications for GLP-1s Beyond Weight Loss
Already established as cornerstone therapies in diabetes and obesity, GLP-1 receptor agonists also show potential in several other indications, including cancer, addiction and neurodegenerative diseases.
December 23, 2024
·
11 min read
·
Tristan Manalac
Bladder cancer
Pfizer’s Subcutaneous PD-1 Blocker Aces Phase III in Bladder Cancer, Carves Niche Versus Keytruda
If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor indicated in combination with BCG for high-risk non-muscle invasive bladder cancer patients who had not previously undergone BCG treatment.
January 10, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer’s Disease Publication of the Company’s Phase 1 INTERCEPT-AD Study, Including Target Engagement, Dosing Regimen and Safety Findings
January 9, 2025
·
7 min read
1 of 75,823
Next
